Company intelligence / Profile preview

Mithra Pharmaceuticals SA

Ownership: Private
Employees: ~270
Development stage: Commercial

Overview

Mithra filed for bankruptcy in 2024 and sold its remaining assets for $188.2 million. Prior to bankruptcy, the company had successfully launched Estelle, the first estetrol-based contraceptive pill in 2021, and was developing Donesta for menopause symptoms.

Therapeutic areas: Women's HealthOncologyEndocrinologyInfectious Diseases
Modalities: Small moleculesPeptidesMonoclonal antibodies
Industry: Biotech

Drug pipeline

5 assets

estetrol

4 more assets in the full pipeline.

Request access →

Partnerships

Gedeon RichterBCI Pharma

Beyond the preview

Go deeper on Mithra Pharmaceuticals SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mithra Pharmaceuticals SA.

Explore the full profile